Discover how Chroma is expanding our impact.

Boston, November 11, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented new preclinical data demonstrating that a single administration of its epigenetic editor efficiently and durably lowered PCSK9 and cholesterol levels in non-human primates in a late-breaking oral presentation at the 2023 American Heart Association (AHA) Scientific Sessions, held November 11-13 in Philadelphia. The data presented provide strong evidence for the potential of Chroma’s epigenetic editing platform to silence expression of PCSK9 in the liver and to induce a durable reduction in low-density lipoprotein-cholesterol (LDL-C) levels, a key factor for reducing…

Boston, MA, November 2, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced that it will present a poster demonstrating the potential of its multiplex epigenetic editing platform at the American Society of Hematology (ASH) 65th Annual Meeting, taking place December 9-12, 2023, in San Diego, CA. The ASH abstract contains data showing the potential of multiplex epigenetic editing to produce functional allogeneic CAR T cells that do not exhibit a graft-versus-host-disease (GVHD) response, resist CD8+ and CD4+ T cell alloresponses, and resist the NK missing-self response normally consequent of reduced MHC…

Boston, MA, September 27, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the addition of innovative biotech business leader Michael A. Kelly to its Board of Directors. “Michael brings decades of strategic finance and business operations experience to Chroma and builds on the deep expertise of our current board and leadership team. We are excited to welcome him as we pursue the promise of epigenetic editing for patients,” said Catherine Stehman-Breen, M.D., Chief Executive Officer of Chroma. Mr. Kelly is the Founder and President of Sentry Hill Partners, LLC, a global…

Boston, MA., September 21, 2023 — Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced it was named to the Endpoints 11 2023 list of the most promising biotechs by Endpoints News. This annual award celebrates companies with leading-edge science that are pioneering the development of new medicines. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma is rapidly advancing a new class of therapeutics that harness epigenetics, nature’s innate mechanism for gene regulation, to achieve unparalleled control of gene expression without cutting, nicking, or altering the DNA sequence. After securing…